Showing papers on "European union published in 2021"

SecureBoost: A Lossless Federated Learning Framework

Abstract: The protection of user privacy is an important concern in machine learning, as evidenced by the rolling out of the General Data Protection Regulation (GDPR) in the European Union (EU) in May 2018 The GDPR is designed to give users more control over their personal data, which motivates us to explore machine learning frameworks for data sharing that do not violate user privacy To meet this goal, in this paper, we propose a novel lossless privacy-preserving tree-boosting system known as SecureBoost in the setting of federated learning This federated-learning system allows the learning process to be jointly conducted over multiple parties with partially common user samples but different feature sets, which corresponds to a vertically partitioned data set An advantage of SecureBoost is that it provides the same level of accuracy as the non privacy-preserving approach while at the same time, reveals no information of each private data provider We formally prove that the SecureBoost framework is as accurate as other non-federated gradient tree-boosting algorithms that concentrate data in one place In addition, we describe information leakage during the protocol execution and propose ways to provably reduce it

European Spatial Planning and Territorial Cooperation

Abstract: Part 1: Introducing The European Dimension of Spatial Planning 1. Introducing the European Union as a Planning Subject 2. Arguing for and against European Spatial Planning 3. The Language Challenge and Terminology Part 2: The Spatial Development Context for European Spatial Planning 4. Spatial Development Trends in Europe and the Key Issues for Spatial Planning 5. Understanding and Representing European Space 6. Spatial Data and Spatial Information Part 3: The Institutional Framework for European Union Spatial Policy Making 7. European Integration and the European Union as a Political System 8. Theoretical Approaches to EU Governance and Policy-Making 9. The institutions of the European Union 10. Non-EU Actors, Organisations and Networks 11. Decision-Making and Policy-Making Processes in the European Union 12. Widening, Deepening and Broadening the EU: Past Experiences and Future Prospects Part 4: The European Spatial Planning Agenda 13. A Model of European Spatial Planning? 14. The Emergence of the European Spatial Planning Agenda 15. The Instruments of European Spatial Planning: Spatial Strategies, Spatial Visions and the Quest for Spatial Coordination 16. The Instruments of European Spatial Planning: Transboundary Territorial Cooperation Programmes and Projects Part 5: EU Spatial Policy: Sectoral Policies and their Territorial Effects 17. EU Economic and Competition Policies 18. EU Cohesion Policy, Regional Development and Disparities 19. EU Transport Policy 20. EU Agriculture and Rural Development Policy 21. EU Environmental Policy and Sustainability Part 6: Towards New Forms ofTerritorial Governance? 22. The Relevance of European Transboundary Cooperation for Spatial Planning 23. The Europeanisation of Domestic Planning Systems 24. Planning Cultures, Professions and Education in the EU 25. Looking Back and Looking Forward: A Critical Reflection on European Spatial Planning as Practice and as a Field of Research

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.

Abstract: This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

Abstract: Summary Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial. We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with standard of care alone in patients admitted to hospital with COVID-19, with indication of oxygen or ventilator support. Methods DisCoVeRy was a phase 3, open-label, adaptive, multicentre, randomised, controlled trial conducted in 48 sites in Europe (France, Belgium, Austria, Portugal, Luxembourg). Adult patients (aged ≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and illness of any duration were eligible if they had clinical evidence of hypoxaemic pneumonia, or required oxygen supplementation. Exclusion criteria included elevated liver enzymes, severe chronic kidney disease, any contraindication to one of the studied treatments or their use in the 29 days before random assignment, or use of ribavirin, as well as pregnancy or breastfeeding. Participants were randomly assigned (1:1:1:1:1) to receive standard of care alone or in combination with remdesivir, lopinavir–ritonavir, lopinavir–ritonavir and interferon beta-1a, or hydroxychloroquine. Randomisation used computer-generated blocks of various sizes; it was stratified on severity of disease at inclusion and on European administrative region. Remdesivir was administered as 200 mg intravenous infusion on day 1, followed by once daily, 1-h infusions of 100 mg up to 9 days, for a total duration of 10 days. It could be stopped after 5 days if the participant was discharged. The primary outcome was the clinical status at day 15 measured by the WHO seven-point ordinal scale, assessed in the intention-to-treat population. Safety was assessed in the modified intention-to-treat population and was one of the secondary outcomes. This trial is registered with the European Clinical Trials Database, EudraCT2020-000936-23, and ClinicalTrials.gov, NCT04315948. Findings Between March 22, 2020, and Jan 21, 2021, 857 participants were enrolled and randomly assigned to remdesivir plus standard of care (n=429) or standard of care only (n=428). 15 participants were excluded from analysis in the remdesivir group, and ten in the control group. At day 15, the distribution of the WHO ordinal scale was: (1) not hospitalised, no limitations on activities (61 [15%] of 414 in the remdesivir group vs 73 [17%] of 418 in the control group); (2) not hospitalised, limitation on activities (129 [31%] vs 132 [32%]); (3) hospitalised, not requiring supplemental oxygen (50 [12%] vs 29 [7%]); (4) hospitalised, requiring supplemental oxygen (76 [18%] vs 67 [16%]); (5) hospitalised, on non-invasive ventilation or high flow oxygen devices (15 [4%] vs 14 [3%]); (6) hospitalised, on invasive mechanical ventilation or extracorporeal membrane oxygenation (62 [15%] vs 79 [19%]); (7) death (21 [5%] vs 24 [6%]). The difference between treatment groups was not significant (odds ratio 0·98 [95% CI 0·77–1·25]; p=0·85). There was no significant difference in the occurrence of serious adverse events between treatment groups (remdesivir, 135 [33%] of 406 vs control, 130 [31%] of 418; p=0·48). Three deaths (acute respiratory distress syndrome, bacterial infection, and hepatorenal syndrome) were considered related to remdesivir by the investigators, but only one by the sponsor's safety team (hepatorenal syndrome). Interpretation No clinical benefit was observed from the use of remdesivir in patients who were admitted to hospital for COVID-19, were symptomatic for more than 7 days, and required oxygen support. Funding European Union Commission, French Ministry of Health, Domaine d'interet majeur One Health Ile-de-France, REACTing, Fonds Erasme-COVID-Universite Libre de Bruxelles, Belgian Health Care Knowledge Centre, Austrian Group Medical Tumor, European Regional Development Fund, Portugal Ministry of Health, Portugal Agency for Clinical Research and Biomedical Innovation. Translation For the French translation of the abstract see Supplementary Materials section.

Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data.

Abstract: Summary Background Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis, which are typically transmitted via respiratory droplets, are leading causes of invasive diseases, including bacteraemic pneumonia and meningitis, and of secondary infections subsequent to post-viral respiratory disease. The aim of this study was to investigate the incidence of invasive disease due to these pathogens during the early months of the COVID-19 pandemic. Methods In this prospective analysis of surveillance data, laboratories in 26 countries and territories across six continents submitted data on cases of invasive disease due to S pneumoniae, H influenzae, and N meningitidis from Jan 1, 2018, to May, 31, 2020, as part of the Invasive Respiratory Infection Surveillance (IRIS) Initiative. Numbers of weekly cases in 2020 were compared with corresponding data for 2018 and 2019. Data for invasive disease due to Streptococcus agalactiae, a non-respiratory pathogen, were collected from nine laboratories for comparison. The stringency of COVID-19 containment measures was quantified using the Oxford COVID-19 Government Response Tracker. Changes in population movements were assessed using Google COVID-19 Community Mobility Reports. Interrupted time-series modelling quantified changes in the incidence of invasive disease due to S pneumoniae, H influenzae, and N meningitidis in 2020 relative to when containment measures were imposed. Findings 27 laboratories from 26 countries and territories submitted data to the IRIS Initiative for S pneumoniae (62 434 total cases), 24 laboratories from 24 countries submitted data for H influenzae (7796 total cases), and 21 laboratories from 21 countries submitted data for N meningitidis (5877 total cases). All countries and territories had experienced a significant and sustained reduction in invasive diseases due to S pneumoniae, H influenzae, and N meningitidis in early 2020 (Jan 1 to May 31, 2020), coinciding with the introduction of COVID-19 containment measures in each country. By contrast, no significant changes in the incidence of invasive S agalactiae infections were observed. Similar trends were observed across most countries and territories despite differing stringency in COVID-19 control policies. The incidence of reported S pneumoniae infections decreased by 68% at 4 weeks (incidence rate ratio 0·32 [95% CI 0·27–0·37]) and 82% at 8 weeks (0·18 [0·14–0·23]) following the week in which significant changes in population movements were recorded. Interpretation The introduction of COVID-19 containment policies and public information campaigns likely reduced transmission of S pneumoniae, H influenzae, and N meningitidis, leading to a significant reduction in life-threatening invasive diseases in many countries worldwide. Funding Wellcome Trust (UK), Robert Koch Institute (Germany), Federal Ministry of Health (Germany), Pfizer, Merck, Health Protection Surveillance Centre (Ireland), SpID-Net project (Ireland), European Centre for Disease Prevention and Control (European Union), Horizon 2020 (European Commission), Ministry of Health (Poland), National Programme of Antibiotic Protection (Poland), Ministry of Science and Higher Education (Poland), Agencia de Salut Publica de Catalunya (Spain), Sant Joan de Deu Foundation (Spain), Knut and Alice Wallenberg Foundation (Sweden), Swedish Research Council (Sweden), Region Stockholm (Sweden), Federal Office of Public Health of Switzerland (Switzerland), and French Public Health Agency (France).

Circular economy strategies for electric vehicle batteries reduce reliance on raw materials

Abstract: The wide adoption of lithium-ion batteries used in electric vehicles will require increased natural resources for the automotive industry. The expected rapid increase in batteries could result in new resource challenges and supply-chain risks. To strengthen the resilience and sustainability of automotive supply chains and reduce primary resource requirements, circular economy strategies are needed. Here we illustrate how these strategies can reduce the extraction of primary raw materials, that is, cobalt supplies. Material flow analysis is applied to understand current and future flows of cobalt embedded in electric vehicle batteries across the European Union. A reference scenario is presented and compared with four strategies: technology-driven substitution and technology-driven reduction of cobalt, new business models to stimulate battery reuse/recycling and policy-driven strategy to increase recycling. We find that new technologies provide the most promising strategies to reduce the reliance on cobalt substantially but could result in burden shifting such as an increase in nickel demand. To avoid the latter, technological developments should be combined with an efficient recycling system. We conclude that more-ambitious circular economy strategies, at both government and business levels, are urgently needed to address current and future resource challenges across the supply chain successfully. New battery chemistry can help reduce the reliance on Co for electric vehicles. However, to avoid burden shifting to other resources such as Ni, circular economy strategies with enhanced battery traceability and recycling could contribute substantially to the reduction of primary Co demand from the automotive industry.

BNT162b2 mRNA COVID-19 Vaccine: First Approval.

Abstract: BNT162b2 (Comirnaty®; BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. BNT162b2 encodes the SARS-CoV-2 spike protein, the expression of which elicits immune responses against the antigen in recipients. In early December 2020, BNT162b2 received a temporary emergency use authorization (EUA) in the UK and, subsequently, a series of approvals or authorizations for emergency use in Bahrain, Canada, Mexico, Saudi Arabia and the USA. Soon after, BNT162b2 received conditional marketing authorizations in Switzerland (19 December 2020) and the EU (21 December 2020) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age and older. BNT162b2 is administered intramuscularly in a two-dose regimen. This article summarizes the milestones in the development of BNT162b2 leading to these first approvals for the prevention of COVID-19.

Legal status of a renewables self-consumer under Polish law in light of Directive (EU) 2018/2001 of the European Parliament and of the Council of 11 December 2018 on the promotion of the use of energy from renewable sources

Abstract: The rapid spread of RES technologies, due to regulatory pressure and a dramatic decrease in their construction and operation costs, makes it possible for citizens to become active participants in the energy market. European Union’s legislation demands that citizens should be empowered to actively participate in the energy market by responding to market signals and in return benefit from lower electricity prices or other incentives. The aim of the article is to present and evaluate the concept of the renewables self-consumer regulated in the Polish Renewable Energy Sources Act in the light of the content of Directive (EU) 2018/2001 of the European Parliament and of the Council of 11th December 2018 on the promotion of the use of energy from renewable sources.

SCOPE 2021: a new scorecard for osteoporosis in Europe

Abstract: This scorecard summarises key indicators of the burden of osteoporosis and its management in the 27 member states of the European Union, as well as the UK and Switzerland. The resulting scorecard elements, assembled on a single sheet, provide a unique overview of osteoporosis in Europe. The scorecard for osteoporosis in Europe (SCOPE) is a project of the International Osteoporosis Foundation (IOF) that seeks to raise awareness of osteoporosis care in Europe. The aim of this project was to develop a scorecard and background documents to draw attention to gaps and inequalities in the provision of primary and secondary prevention of fractures due to osteoporosis. The SCOPE panel reviewed the information available on osteoporosis and the resulting fractures for each of the 27 countries of the European Union plus the UK and Switzerland (termed EU27+2). The information obtained covered four domains: background information (e.g. the burden of osteoporosis and fractures), policy framework, service provision and service uptake, e.g. the proportion of men and women at high risk that do not receive treatment (the treatment gap). There was a marked difference in fracture risk among the EU27+2 countries. Of concern was the marked heterogeneity in the policy framework, service provision and service uptake for osteoporotic fracture that bore little relation to the fracture burden. For example, despite the wide availability of treatments to prevent fractures, in the majority of the EU27+2, only a minority of patients at high risk receive treatment even after their first fracture. The elements of each domain in each country were scored and coded using a traffic light system (red, orange, green) and used to synthesise a scorecard. The resulting scorecard elements, assembled on a single sheet, provide a unique overview of osteoporosis in Europe. The scorecard enables healthcare professionals and policy makers to assess their country’s general approach to the disease and provide indicators to inform the future provision of healthcare.

Divided by the Vote: Affective Polarization in the Wake of the Brexit Referendum

Abstract: A well-functioning democracy requires a degree of mutual respect and a willingness to talk across political divides. Yet numerous studies have shown that many electorates are polarized along partisan lines, with animosity towards the partisan out-group. This article further develops the idea of affective polarization, not by partisanship, but instead by identification with opinion-based groups. Examining social identities formed during Britain's 2016 referendum on European Union membership, the study uses surveys and experiments to measure the intensity of partisan and Brexit-related affective polarization. The results show that Brexit identities are prevalent, felt to be personally important and cut across traditional party lines. These identities generate affective polarization as intense as that of partisanship in terms of stereotyping, prejudice and various evaluative biases, convincingly demonstrating that affective polarization can emerge from identities beyond partisanship.

Persistence of SARS-CoV-2 specific B- and T-cell responses in convalescent COVID-19 patients 6-8 months after the infection.

Abstract: Summary Background Monitoring the adaptive immune responses during the natural course of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection provides useful information for the development of vaccination strategies against this virus and its emerging variants. We thus profiled the serum anti-SARS-CoV-2 antibody (Ab) levels and specific memory B and T cell responses in convalescent coronavirus disease 2019 (COVID-19) patients. Methods A total of 119 samples from 88 convalescent donors who experienced mild to critical disease were tested for the presence of elevated anti-spike and anti-receptor binding domain Ab levels over a period of 8 months. In addition, the levels of SARS-CoV-2 neutralizing Abs and specific memory B and T cell responses were tested in a subset of samples. Findings Anti-SARS-CoV-2 Abs were present in 85% of the samples collected within 4 weeks after the onset of symptoms in COVID-19 patients. Levels of specific immunoglobulin M (IgM)/IgA Abs declined after 1 month, while levels of specific IgG Abs and plasma neutralizing activities remained relatively stable up to 6 months after diagnosis. Anti-SARS-CoV-2 IgG Abs were still present, although at a significantly lower level, in 80% of the samples collected at 6–8 months after symptom onset. SARS-CoV-2-specific memory B and T cell responses developed with time and were persistent in all of the patients followed up for 6–8 months. Conclusions Our data suggest that protective adaptive immunity following natural infection of SARS-CoV-2 may persist for at least 6–8 months, regardless of disease severity. Development of medium- or long-term protective immunity through vaccination may thus be possible. Funding This project was supported by the European Union's Horizon 2020 research and innovation programme (ATAC, no. 101003650), the Italian Ministry of Health (Ricerca Finalizzata grant no. GR-2013-02358399), the Center for Innovative Medicine, and the Swedish Research Council. J.A. was supported by the SciLifeLab/KAW national COVID-19 research program project grant 2020.

Digitization, Digital Twins, Blockchain, and Industry 4.0 as Elements of Management Process in Enterprises in the Energy Sector

Abstract: In the 21st century, it is becoming increasingly clear that human activities and the activities of enterprises affect the environment. Therefore, it is important to learn about the methods in which companies minimize the negative effects of their activities. The article presents the steps taken and innovative actions carried out by enterprises in the energy sector. The article analyzes innovative activities undertaken and implemented by enterprises from the energy sector. The relationships between innovative strategies, including, inter alia, digitization, and Industry 4.0 solutions, in the development of companies and the achieved results concerning sustainable development and environmental impact. Digitization has far exceeded traditional productivity improvement ranges of 3–5% per year, with a clear cost improvement potential of well above 25%. Enterprises on a large scale make attempts to increase energy efficiency by implementing the state-of-the-art innovative technical and technological solutions, which increase reliability and durability (material and mechanical engineering). Digitization of energy companies allows them to reduce operating costs and increases efficiency. With digital advances, the useful life of an energy plant can be increased up to 30%. Advanced technologies, blockchain, and the use of intelligent networks enables the activation of prosumers in the electricity market. Reducing energy consumption in industry and at the same time increasing energy efficiency for which the European Union is fighting in the clean air package for all Europeans have a positive impact on environmental protection, sustainable development, and the implementation of the decarbonization program.

Deep Dive into Plastic Monomers, Additives, and Processing Aids.

Abstract: A variety of chemical substances used in plastic production may be released throughout the entire life cycle of the plastic, posing risks to human health, the environment, and recycling systems. Only a limited number of these substances have been widely studied. We systematically investigate plastic monomers, additives, and processing aids on the global market based on a review of 63 industrial, scientific, and regulatory data sources. In total, we identify more than 10'000 relevant substances and categorize them based on substance types, use patterns, and hazard classifications wherever possible. Over 2'400 substances are identified as substances of potential concern as they meet one or more of the persistence, bioaccumulation, and toxicity criteria in the European Union. Many of these substances are hardly studied according to SciFinder (266 substances), are not adequately regulated in many parts of the world (1'327 substances), or are even approved for use in food-contact plastics in some jurisdictions (901 substances). Substantial information gaps exist in the public domain, particularly on substance properties and use patterns. To transition to a sustainable circular plastic economy that avoids the use of hazardous chemicals, concerted efforts by all stakeholders are needed, starting by increasing information accessibility.

Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis.

Abstract: The presence of SARS-CoV-2 was officially documented in Europe at the end of February 2020. Despite many observations, the real impact of COVID-19 in the European Union (EU), its underlying factors and their contribution to mortality and morbidity outcomes were never systematically investigated. The aim of the present work is to provide an overview and a meta-analysis of main predictors and of country differences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-associated mortality rate (MR) in hospitalized patients. Out of 3714 retrieved articles, 87 studies were considered, including 35,486 patients (mean age 60.9 ± 8.2 years) and 5867 deaths. After adjustment for confounders, diabetes mellitus was the best predictors of MR in an age- and sex-dependent manner, followed by chronic pulmonary obstructive diseases and malignancies. In both the US and Europe, MR was higher than that reported in Asia (25[20;29] % and 20[17;23] % vs. 13[10;17]%; both p < 0.02). Among clinical parameters, dyspnea, fatigue and myalgia, along with respiratory rate, emerged as the best predictors of MR. Finally, reduced lymphocyte and platelet count, along with increased D-dimer levels, all significantly contributed to increased mortality. The optimization of glucose profile along with an adequate thrombotic complications preventive strategy must become routine practice in diseased SARS-CoV-2 infected patients.

A review on energy storage and demand side management solutions in smart energy islands

Abstract: European Union has definitely identified the priorities towards sustainable and low-carbon energy systems recognizing a key role to islands that have been described as ideal sites to develop and test innovative strategies and solutions that will then boost the transition on the mainland. Nevertheless, the integration of Variable Renewable Energy Sources (vRES) into the electricity grid are already causing technical problems to island grids thus making grid flexibility a key topic. In the past, since power plants were completely manageable while the load was unpredictable, the grid flexibility was supplied by traditional power plants; but now, due to vRES, the variability and unpredictability has moved to the generation side and the opposite shift has happened to flexibility agents. This paper deals with solutions that improve the ability of the grid to cope with vRES unpredictability such as energy storage technologies and all the solutions offered by sector coupling strategies. Particularly, this research focus on solutions that deals with such solutions in the insular contexts. Several solutions have been presented concluding that battery energy systems and pumped hydro energy storage are the most used technologies in islands. As regard sector coupling and Demand Side Management solutions, all the analysed solutions showed relevant results in terms of i) reduction of excess electricity production and ii) increased grid ability of hosting vRES. Nevertheless, some of the current gaps in literature have been pinpointed and future research challenge and opportunities have been suggested.

A proposed global layout of carbon capture and storage in line with a 2 °C climate target

Abstract: A straightforward global layout of carbon capture, utilization and storage (CCUS) is imperative for limiting global warming well below 2 °C. Here, we propose a cost-effective strategy for matching carbon sources and sinks on a global scale. Results show 3,093 carbon clusters and 432 sinks in 85 countries and regions are selected to achieve 92 GtCO2 mitigation by CCUS, 64% of which will be sequestered into sedimentary basins for aquifer storage and 36% will be used for CO2-EOR (enhanced oil recovery). Of the identified source–sink matching, 80% are distributed within 300 km and are mainly located in China, the United States, the European Union, Russia and India. The total cost is ~0.12% of global cumulative gross domestic product. Of countries with CO2-EOR, 75% will turn into profitable at the oil price over US$100 per barrel. These findings indicate our proposed layout is economically feasible. However, its implementation requires global collaboration on financial and technological transfer. Carbon capture, utilization and storage (CCUS) will be required to meet climate targets. An economically feasible global CCUS layout can be achieved by capturing the carbon sources in 85 regions and mitigating with 59 GtCO2 sequestration and aquifer storage and 33 GtCO2-enhanced oil recovery.

Highly selective and stable nickel catalysts supported on ceria promoted with Sm2O3, Pr2O3 and MgO for the CO2 methanation reaction

Abstract: GIS is grateful for financial support by Greece and ESF through the Operational Programme «Human Resources Development, Education and Lifelong Learning» in the context of the project “Strengthening Human Resources Research Potential via Doctorate Research” (MIS-5000432), implemented by the State Scholarships Foundation (IKY). NDC is grateful to the Research Committee of UOWM for financial support through grant no. 80304. IVY and MAG are grateful for financial support from the European Union and Greek national funds through the operational program Competitiveness, Entrepreneurship and Innovation, under the call Research-Create-Innovate (Project code: T1EDK-00782). SAK, AAK and KP acknowledge the financial support from the Abu Dhabi Department of Education and Knowledge (ADEK) under the AARE 2019-233 grant and support by the Khalifa University of Science and Technology under Award No. RC2-2018-024.

European Green Deal – legal and financial challenges of the climate change

Abstract: The European Green Deal announced by the European Commission in December 2019 is a roadmap meant to foster the transition of the European Union towards the climate-neutral economy by reducing carbon emissions towards 55% by 2030 and achieving carbon neutrality by 2050. By putting the EGD in a boarder perspective of evolving, constitutional rationale of environmental protection in the EU legal order, this contribution examines horizontal, legal dimension and financial implications of the green transition. The challenge ahead of the Union is now how to transform the ambitious climate agenda into efficient legal and economic instruments ‘in a fair way, leaving no one behind’. This paper argues that EGD is a great opportunity, but in order to turn it into a success, it must be strongly anchored in the concepts pertaining to the constitutional framework of the EU legal order, in particular, the concepts of solidarity, sustainable development and high level of environmental protection.

A Review of Bioplastics and Their Adoption in the Circular Economy.

Abstract: The European Union is working towards the 2050 net-zero emissions goal and tackling the ever-growing environmental and sustainability crisis by implementing the European Green Deal. The shift towards a more sustainable society is intertwined with the production, use, and disposal of plastic in the European economy. Emissions generated by plastic production, plastic waste, littering and leakage in nature, insufficient recycling, are some of the issues addressed by the European Commission. Adoption of bioplastics–plastics that are biodegradable, bio-based, or both–is under assessment as one way to decouple society from the use of fossil resources, and to mitigate specific environmental risks related to plastic waste. In this work, we aim at reviewing the field of bioplastics, including standards and life cycle assessment studies, and discuss some of the challenges that can be currently identified with the adoption of these materials.

Urban population exposure to air pollution in Europe over the last decades

Abstract: The paper presents an overview of air quality in the 27 member countries of the European Union (EU) and the United Kingdom (previous EU-28), from 2000 to 2017. We reviewed the progress made towards meeting the air quality standards established by the EU Ambient Air Quality Directives (European Council Directive 2008/50/EC) and the World Health Organization (WHO) Air Quality Guidelines by estimating the trends (Mann-Kendal test) in national emissions of main air pollutants, urban population exposure to air pollution, and in mortality related to exposure to ambient fine particles (PM2.5) and tropospheric ozone (O3). Despite significant reductions of emissions (e.g., sulfur oxides: ~ 80%, nitrogen oxides: ~ 46%, non-methane volatile organic compounds: ~ 44%, particulate matters with a diameter lower than 2.5 µm and 10 µm: ~ 30%), the EU-28 urban population was exposed to PM2.5 and O3 levels widely exceeding the WHO limit values for the protection of human health. Between 2000 and 2017, the annual PM2.5-related number of deaths decreased (- 4.85 per 106 inhabitants) in line with a reduction of PM2.5 levels observed at urban air quality monitoring stations. The rising O3 levels became a major public health issue in the EU-28 cities where the annual O3-related number of premature deaths increased (+ 0.55 deaths per 106 inhabitants). To achieve the objectives of the Ambient Air Quality Directives and mitigate air pollution impacts, actions need to be urgently taken at all governance levels. In this context, greening and re‐naturing cities and the implementation of fresh air corridors can help meet air quality standards, but also answer to social needs, as recently highlighted by the COVID-19 lockdowns.